カテゴリー： Research Dive, 世界, 医療/バイオ

抗核抗体検査の世界市場2022-2031：機会分析・産業予測

◆英語タイトル：Antinuclear Antibody Test Market, by Product (Reagents & Assay Kits, Systems and Software & Services), Technique (ELISA, Immunofluorescence Assay and Multiplex Assay), Application (Rheumatoid Arthritis, Systemic Lupus Erythematosus, Sjogren’s syndrome, Scleroderma, and Others), End Use (Hospitals, Clinical Laboratories, Physician Office Laboratories, and Others), Regional Outlook (North America, Europe, Asia-Pacific, and LAMEA): Global Opportunity Analysis And Industry Forecast, 2022-2031

Research Diveが発行した調査報告書（RDV23MA015）◆商品コード：RDV23MA015
◆発行会社（リサーチ会社）：Research Dive
◆発行日：2022年9月22日
◆ページ数：300
◆レポート形式：英語 / PDF
◆納品方法：Eメール
◆調査対象地域：グローバル
◆産業分野：生命科学
◆販売価格オプション（消費税別）
Single UserUSD5,700 ⇒換算￥866,400見積依頼/購入/質問フォーム
5 UserUSD8,700 ⇒換算￥1,322,400見積依頼/購入/質問フォーム
Enterprise UserUSD10,700 ⇒換算￥1,626,400見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

リサーチ・ダイブ社では、世界の抗核抗体検査市場規模が2021年1,294.90百万ドルから2031年には4,999.40百万ドルになり、年平均14.97%成長すると推測しています。本調査報告書では、抗核抗体検査の世界市場について多面的に調べ、調査手法、調査範囲、エグゼクティブサマリー、市場概要、製品別（試薬＆アッセイキット、システム/ソフトウェア/サービス）分析、技術別（ELISA、免疫蛍光アッセイ、マルチプレックスアッセイ）分析、用途別（関節リウマチ、全身性エリテマトーデス、シェーグレン症候群、強皮症、その他）分析、最終用途別（病院、臨床研究所、医師オフィス研究所、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米・中東・アフリカ）分析、競争状況などの内容を掲載しています。尚、企業情報として、Erba Diagnostics, Bio-Rad Laboratories, Inc., Trinity Biotech Plc., Thermo Fisher Scientific, Antibodies Incorporated, EUROIMMUN Medizinische Labordiagnostika AG, Immuno Concepts NA Ltd., Inova Diagnostics, Inc. and ZEUS Scientific, Inc.などが記載されています。
・調査手法
・調査範囲
・エグゼクティブサマリー
・市場概要
・世界の抗核抗体検査市場規模：製品別
- 試薬＆アッセイキットの市場規模
- システム/ソフトウェア/サービスの市場規模
・世界の抗核抗体検査市場規模：技術別
- ELISAの市場規模
- 免疫蛍光アッセイの市場規模
- マルチプレックスアッセイの市場規模
・世界の抗核抗体検査市場規模：用途別
- 関節リウマチ用抗核抗体検査の市場規模
- 全身性エリテマトーデス用抗核抗体検査の市場規模
- シェーグレン症候群用抗核抗体検査の市場規模
- 強皮症用抗核抗体検査の市場規模
- その他用途の市場規模
・世界の抗核抗体検査市場規模：最終用途別
- 病院における市場規模
- 臨床研究所における市場規模
- 医師オフィス研究所における市場規模
- その他最終用途における市場規模
・世界の抗核抗体検査市場規模：地域別
- 北米の抗核抗体検査市場規模
- ヨーロッパの抗核抗体検査市場規模
- アジア太平洋の抗核抗体検査市場規模
- 中南米の抗核抗体検査市場規模
- 中東/アフリカの抗核抗体検査市場規模
・競争状況
・企業情報

According to Research Dive analysis, the global antinuclear antibody test market is anticipated to generate a revenue of $ 4,999.40 million by 2031, increasing from $ 1,294.90 million in 2021, at a healthy CAGR of 14.97%

COVID-19 Impact on the Global Antinuclear Antibody Test Market:
The spread of the novel coronavirus had created havoc across the Industrial verticals by disturbing the supply chain. According to World Metres, there were 67.5 million COVID-19 cases worldwide on December 7th, 2020, with 1.5 million fatalities. To contain the spread of novel coronavirus, government bodies and Municipal corporations impose lockdowns and restrict the movement of transportation.

Also, the implementation of social distancing norms and lack of transportation facilities lead to a shortage of workers, thereby hampering the production and distribution of goods. However, the demand for ANA test reagents and kits grew during the pandemic. It was observed that COVID-19 has led to an increase in antinuclear antibodies in most patients. As a preventive measure, the demand for ANA test kits grew during the pandemic.

Post-COVID-19, government, and pharmaceutical companies are taking several initiatives to increase awareness about autoimmune diseases. Furthermore, increasing demand for ANA tests among the geriatric population will boost the demand for ANA tests during the forecast period.

Antinuclear Antibody Test Market Analysis:
An antinuclear antibody test is used to screen for the presence of antinuclear antibodies in the specimen. Antinuclear antibody testing is becoming more and more popular as a way to diagnose autoimmune diseases such as rheumatoid arthritis, Systemic Lupus Erythematosus, Sjögren’s Syndrome, and others. The demand for antinuclear antibody testing has increased significantly due to the incidence of autoimmune disorders and rising public awareness. In the approaching years, it is anticipated that all of these factors will increase the demand for antinuclear antibody tests.
The National Institutes of Health (NIH), under the direction of the National Institute of Allergy and Infectious Diseases, created the Autoimmune Diseases Coordinating Committee (ADCC) (NIAID) to investigate the root causes of the rising prevalence. It was observed that the rising consumption of western food items such as pizza, burgers, and fried chicken, among others, can be responsible for the rising prevalence of autoimmune diseases. The government initiatives and growing awareness of autoimmune illnesses have had a substantial positive impact on the market for antinuclear antibody tests worldwide.

Nowadays, diagnostic labs and hospitals are equipped with advanced testing equipment. Besides, some diagnostic labs and hospitals are investing in lab automation. To operate this sophisticated equipment, skilled and trained professionals are required. However, there is a dearth of skilled and trained professionals in most countries. The lack of skilled and trained professionals will hinder the growth of the ANA test market.
Based on product, the reagents & assay kits sub-segment held a major share in 2021 estimated to show the fastest growth during the forecast period. The market for reagents & assays is projected to reach $3,153.10 million by 2031. The rising number of ANA tests and the use of reagents assay kits for screening specimens is the key factor driving the demand for the reagents & kits market during the forecast period.

Based on Technique, the ELISA sub-segment is anticipated to have dominated the market share in 2021 and is predicted to show the fastest growth during the forecast period. The market size for the ELISA sub-segment is estimated to be $2,167.70 million by 2031. Increasing adoption and use of the ELISA technique for rapid diagnosis of autoimmune disease is the major factor propelling the ELISA technique market during the forecast period.

Based on Application, the rheumatoid arthritis sub-segment is predicted to show the fastest growth rate and generate a revenue of $3,622.40 million by 2031. The growing incidence of rheumatoid arthritis in the geriatric population is the main factor propelling the demand for ANA tests in rheumatoid arthritis application.

Based on End-use, the hospitals is predicted to be the most dominant sub-segment and generate a revenue of $1,907.60 million by 2031. The hospital sub-segment market is expected to be driven by an increase in patient satisfaction, outpatient services, and expanded home care facilities offered by hospitals.

Based on geographical scope, the Asia-Pacific antinuclear antibody test market is anticipated to grow at a CAGR of 17.1% from 2022 – 2031. Increasing collaborations among healthcare service providers and the growing incidence of autoimmune diseases such as rheumatoid arthritis are predicted to be major driving factors for the regional market in the estimated period.

The companies involved in the global antinuclear antibody market are Erba Diagnostics, Bio-Rad Laboratories, Inc., Trinity Biotech Plc., Thermo Fisher Scientific, Antibodies Incorporated, EUROIMMUN Medizinische Labordiagnostika AG, Immuno Concepts NA Ltd., Inova Diagnostics, Inc. and ZEUS Scientific, Inc.”

❖ レポートの目次 ❖

1.Research Methodology

1.1.Desk Research
1.2.Real time insights and validation
1.3.Forecast model
1.4.Assumptions and forecast parameters
1.5.Market size estimation

1.5.1.Top-down approach
1.5.2.Bottom-up approach

2.Report Scope

2.1.Market definition
2.2.Key objectives of the study
2.3.Report overview
2.4.Market segmentation
2.5.Overview of the impact of COVID-19 on global antinuclear antibody test market

3.Executive Summary

4.Market Overview

4.1.Introduction
4.2.Growth impact forces

4.2.1.Drivers
4.2.2.Restraints
4.2.3.Opportunities

4.3.Market value chain analysis

4.3.1.List of raw material suppliers
4.3.2.List of manufacturers
4.3.3.List of distributors

4.4.Innovation & sustainability matrices

4.4.1.Technology matrix
4.4.2.Regulatory matrix

4.5.Porter’s five forces analysis

4.5.1.Bargaining power of suppliers
4.5.2.Bargaining power of consumers
4.5.3.Threat of substitutes
4.5.4.Threat of new entrants
4.5.5.Competitive rivalry intensity

4.6.PESTLE analysis

4.6.1.Political
4.6.2.Economical
4.6.3.Social
4.6.4.Technological
4.6.5.Environmental

4.7.Impact of COVID-19 on antinuclear antibody test market

4.7.1.Pre-COVID market scenario
4.7.2.Post-COVID market scenario

5.Antinuclear Antibody Test Market Analysis, by Product

5.1.Overview

5.2.Reagents & Assay Kits

5.2.1.Definition, key trends, growth factors, and opportunities
5.2.2.Market size analysis, by region, 2021-2031
5.2.3.Market share analysis, by country, 2021-2031

5.3.Systems

5.3.1.Definition, key trends, growth factors, and opportunities
5.3.2.Market size analysis, by region, 2021-2031
5.3.3.Market share analysis, by country, 2021-2031

5.4.Software & Services

5.4.1.Definition, key trends, growth factors, and opportunities
5.4.2.Market size analysis, by region, 2021-2031
5.4.3.Market share analysis, by country, 2021-2031

5.5.Research Dive Exclusive Insights

5.5.1.Market attractiveness
5.5.2.Competition heatmap

6.Antinuclear Antibody Test Market Analysis, by Technique

6.1.ELISA

6.1.1.Definition, key trends, growth factors, and opportunities
6.1.2.Market size analysis, by region, 2021-2031
6.1.3.Market share analysis, by country, 2021-2031

6.2.Immunofluorescence Assay

6.2.1.Definition, key trends, growth factors, and opportunities
6.2.2.Market size analysis, by region, 2021-2031
6.2.3.Market share analysis, by country, 2021-2031

6.3.Multiplex Assay

6.3.1.Definition, key trends, growth factors, and opportunities
6.3.2.Market size analysis, by region, 2021-2031
6.3.3.Market share analysis, by country, 2021-2031

6.4.Research Dive Exclusive Insights

6.4.1.Market attractiveness
6.4.2.Competition heatmap

7.Antinuclear Antibody Test Market Analysis, by Application

7.1.Rheumatoid Arthritis

7.1.1.Definition, key trends, growth factors, and opportunities
7.1.2.Market size analysis, by region, 2021-2031
7.1.3.Market share analysis, by country, 2021-2031

7.2.Systemic Lupus Erythematosus

7.2.1.Definition, key trends, growth factors, and opportunities
7.2.2.Market size analysis, by region, 2021-2031
7.2.3.Market share analysis, by country, 2021-2031

7.3.Sjogren’s Syndrome

7.3.1.Definition, key trends, growth factors, and opportunities
7.3.2.Market size analysis, by region, 2021-2031
7.3.3.Market share analysis, by country, 2021-2031

7.4.Scleroderma

7.4.1.Definition, key trends, growth factors, and opportunities
7.4.2.Market size analysis, by region, 2021-2031
7.4.3.Market share analysis, by country, 2021-2031

7.5.Others

7.5.1.Definition, key trends, growth factors, and opportunities
7.5.2.Market size analysis, by region, 2021-2031
7.5.3.Market share analysis, by country, 2021-2031

7.6.Research Dive Exclusive Insights

7.6.1.Market attractiveness
7.6.2.Competition heatmap

8.Antinuclear Antibody Test Market Analysis, by End-use

8.1.Hospitals

8.1.1.Definition, key trends, growth factors, and opportunities
8.1.2.Market size analysis, by region, 2021-2031
8.1.3.Market share analysis, by country, 2021-2031

8.2. Clinical Laboratories

8.2.1.Definition, key trends, growth factors, and opportunities
8.2.2.Market size analysis, by region, 2021-2031
8.2.3.Market share analysis, by country, 2021-2031

8.3.Physician Office Laboratories

8.3.1.Definition, key trends, growth factors, and opportunities
8.3.2.Market size analysis, by region, 2021-2031
8.3.3.Market share analysis, by country, 2021-2031

8.4.Others

8.4.1.Definition, key trends, growth factors, and opportunities
8.4.2.Market size analysis, by region, 2021-2031
8.4.3.Market share analysis, by country, 2021-2031

8.5.Research Dive Exclusive Insights

8.5.1.Market attractiveness
8.5.2.Competition heatmap

9.Antinuclear Antibody Test Market, by Region

9.1.North America

9.1.1.U.S.

9.1.1.1.Market size analysis, by Product, 2021-2031
9.1.1.2.Market size analysis, by Technique, 2021-2031
9.1.1.3.Market size analysis, by Application, 2021-2031
9.1.1.4.Market size analysis, by End-use, 2021-2031

9.1.2.Canada

9.1.2.1.Market size analysis, by Product, 2021-2031
9.1.2.2.Market size analysis, by Technique, 2021-2031
9.1.2.3.Market size analysis, by Application, 2021-2031
9.1.2.4.Market size analysis, by End-use, 2021-2031

9.1.3.Mexico

9.1.3.1.Market size analysis, by Product, 2021-2031
9.1.3.2.Market size analysis, by Technique, 2021-2031
9.1.3.3.Market size analysis, by Application, 2021-2031
9.1.3.4.Market size analysis, by End-use, 2021-2031

9.1.4.Research Dive Exclusive Insights

9.1.4.1.Market attractiveness
9.1.4.2.Competition heatmap

9.2.Europe

9.2.1.Germany

9.2.1.1.Market size analysis, by Product, 2021-2031
9.2.1.2.Market size analysis, by Technique, 2021-2031
9.2.1.3.Market size analysis, by Application, 2021-2031
9.2.1.4.Market size analysis, by End-use, 2021-2031

9.2.2.UK

9.2.2.1.Market size analysis, by Product, 2021-2031
9.2.2.2.Market size analysis, by Technique, 2021-2031
9.2.2.3.Market size analysis, by Application, 2021-2031
9.2.2.4.Market size analysis, by End-use, 2021-2031

9.2.3.France

9.2.3.1.Market size analysis, by Product, 2021-2031
9.2.3.2.Market size analysis, by Technique, 2021-2031
9.2.3.3.Market size analysis, by Application, 2021-2031
9.2.3.4.Market size analysis, by End-use, 2021-2031

9.2.4.Spain

9.2.4.1.Market size analysis, by Product, 2021-2031
9.2.4.2.Market size analysis, by Technique, 2021-2031
9.2.4.3.Market size analysis, by Application, 2021-2031
9.2.4.4.Market size analysis, by End-use, 2021-2031

9.2.5.Italy

9.2.5.1.Market size analysis, by Product, 2021-2031
9.2.5.2.Market size analysis, by Technique, 2021-2031
9.2.5.3.Market size analysis, by Application, 2021-2031
9.2.5.4.Market size analysis, by End-use, 2021-2031

9.2.6.Rest of Europe

9.2.6.1.Market size analysis, by Product, 2021-2031
9.2.6.2.Market size analysis, by Technique, 2021-2031
9.2.6.3.Market size analysis, by Application, 2021-2031
9.2.6.4.Market size analysis, by End-use, 2021-2031

9.2.7.Research Dive Exclusive Insights

9.2.7.1.Market attractiveness
9.2.7.2.Competition heatmap

9.3.Asia-Pacific

9.3.1.China

9.3.1.1.Market size analysis, by Product, 2021-2031
9.3.1.2.Market size analysis, by Technique, 2021-2031
9.3.1.3.Market size analysis, by Application, 2021-2031
9.3.1.4.Market size analysis, by End-use, 2021-2031

9.3.2.Japan

9.3.2.1.Market size analysis, by Product, 2021-2031
9.3.2.2.Market size analysis, by Technique, 2021-2031
9.3.2.3.Market size analysis, by Application, 2021-2031
9.3.2.4.Market size analysis, by End-use, 2021-2031

9.3.3.India

9.3.3.1.Market size analysis, by Product, 2021-2031
9.3.3.2.Market size analysis, by Technique, 2021-2031
9.3.3.3.Market size analysis, by Application, 2021-2031
9.3.3.4.Market size analysis, by End-use, 2021-2031

9.3.4.Australia

9.3.4.1.Market size analysis, by Product, 2021-2031
9.3.4.2.Market size analysis, by Technique, 2021-2031
9.3.4.3.Market size analysis, by Application, 2021-2031
9.3.4.4.Market size analysis, by End-use, 2021-2031

9.3.5.South Korea

9.3.5.1.Market size analysis, by Product, 2021-2031
9.3.5.2.Market size analysis, by Technique, 2021-2031
9.3.5.3.Market size analysis, by Application, 2021-2031
9.3.5.4.Market size analysis, by End-use, 2021-2031

9.3.6.Rest of Asia-Pacific

9.3.6.1.Market size analysis, by Product, 2021-2031
9.3.6.2.Market size analysis, by Technique, 2021-2031
9.3.6.3.Market size analysis, by Application, 2021-2031
9.3.6.4.Market size analysis, by End-use, 2021-2031

9.3.7.Research Dive Exclusive Insights

9.3.7.1.Market attractiveness
9.3.7.2.Competition heatmap

9.4.LAMEA

9.4.1.Brazil

9.4.1.1.Market size analysis, by Product, 2021-2031
9.4.1.2.Market size analysis, by Technique, 2021-2031
9.4.1.3.Market size analysis, by Application, 2021-2031
9.4.1.4.Market size analysis, by End-use, 2021-2031

9.4.2.Saudi Arabia

9.4.2.1.Market size analysis, by Product, 2021-2031
9.4.2.2.Market size analysis, by Technique, 2021-2031
9.4.2.3.Market size analysis, by Application, 2021-2031
9.4.2.4.Market size analysis, by End-use, 2021-2031

9.4.3.UAE

9.4.3.1.Market size analysis, by Product, 2021-2031
9.4.3.2.Market size analysis, by Technique, 2021-2031
9.4.3.3.Market size analysis, by Application, 2021-2031
9.4.3.4.Market size analysis, by End-use, 2021-2031

9.4.4.South Africa

9.4.4.1.Market size analysis, by Product, 2021-2031
9.4.4.2.Market size analysis, by Technique, 2021-2031
9.4.4.3.Market size analysis, by Application, 2021-2031
9.4.4.4.Market size analysis, by End-use, 2021-2031

9.4.5.Rest of LAMEA

9.4.5.1.Market size analysis, by Product, 2021-2031
9.4.5.2.Market size analysis, by Technique, 2021-2031
9.4.5.3.Market size analysis, by Application, 2021-2031
9.4.5.4.Market size analysis, by End-use, 2021-2031

9.4.6.Research Dive Exclusive Insights

9.4.6.1.Market attractiveness
9.4.6.2.Competition heatmap

10.Competitive Landscape

10.1.Top winning strategies, 2021

10.1.1.By strategy
10.1.2.By year

10.2.Strategic overview

10.3.Market share analysis, 2021

11.Company Profiles

11.1.Erba Diagnostics

11.1.1.Overview
11.1.2.Business segments
11.1.3.Product portfolio
11.1.4.Financial performance
11.1.5.Recent developments
11.1.6.SWOT analysis

11.2.Bio-Rad Laboratories, Inc.

11.2.1.Overview
11.2.2.Business segments
11.2.3.Product portfolio
11.2.4.Financial performance
11.2.5.Recent developments
11.2.6.SWOT analysis

11.3.Trinity Biotech Plc.

11.3.1.Overview
11.3.2.Business segments
11.3.3.Product portfolio
11.3.4.Financial performance
11.3.5.Recent developments
11.3.6.SWOT analysis

11.4.Thermo Fisher Scientific

11.4.1.Overview
11.4.2.Business segments
11.4.3.Product portfolio
11.4.4.Financial performance
11.4.5.Recent developments
11.4.6.SWOT analysis

11.5.Antibodies Incorporated

11.5.1.Overview
11.5.2.Business segments
11.5.3.Product portfolio
11.5.4.Financial performance
11.5.5.Recent developments
11.5.6.SWOT analysis
11.6.EUROIMMUN Medizinische Labordiagnostika AG

11.6.1.Overview

11.6.2.Business segments
11.6.3.Product portfolio
11.6.4.Financial performance
11.6.5.Recent developments
11.6.6.SWOT analysis

11.7.Immuno Concepts NA Ltd.

11.7.1.Overview
11.7.2.Business segments
11.7.3.Product portfolio
11.7.4.Financial performance
11.7.5.Recent developments
11.7.6.SWOT analysis

11.8.Inova Diagnostics, Inc.

11.8.1.Overview
11.8.2.Business segments
11.8.3.Product portfolio
11.8.4.Financial performance
11.8.5.Recent developments
11.8.6.SWOT analysis

11.9.ZEUS Scientific, Inc.

11.9.1.Overview
11.9.2.Business segments
11.9.3.Product portfolio
11.9.4.Financial performance
11.9.5.Recent developments
11.9.6.SWOT analysis

11.10.Alere Inc.

11.10.1.Overview
11.10.2.Business segments
11.10.3.Product portfolio
11.10.4.Financial performance
11.10.5.Recent developments
11.10.6.SWOT analysis

12.Appendix

12.1.Parent & peer market analysis
12.2.Premium insights from industry experts
12.3.Related reports”



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 抗核抗体検査の世界市場2022-2031：機会分析・産業予測(Antinuclear Antibody Test Market, by Product (Reagents & Assay Kits, Systems and Software & Services), Technique (ELISA, Immunofluorescence Assay and Multiplex Assay), Application (Rheumatoid Arthritis, Systemic Lupus Erythematosus, Sjogren’s syndrome, Scleroderma, and Others), End Use (Hospitals, Clinical Laboratories, Physician Office Laboratories, and Others), Regional Outlook (North America, Europe, Asia-Pacific, and LAMEA): Global Opportunity Analysis And Industry Forecast, 2022-2031)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 気道管理デバイスの世界市場2022-2031：機会分析・産業予測
  • アレルギー診断の世界市場2022-2031：機会分析・産業予測
  • 外付け排尿管理製品の世界市場2022-2031：機会分析・産業予測
  • 左心耳 (LAA) 閉鎖デバイスの世界市場2022-2031：機会分析・産業予測
  • 凝固検査の世界市場2022-2031：機会分析・産業予測

    • ◆H&Iグローバルリサーチのお客様（例）◆